Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
donor-derived NK cell infusion
Chongqing Precision Biotech Co., Ltd
Non-small Cell Lung Cancer
1 trial -
pCAR-19B cells
Chongqing Precision Biotech Co., Ltd
Acute Lymphoblastic Leukemia
2 trials -
A first in human study of people with chronic hepatitis B, where all participants will receive the new drug PBGENE-HBV. This study will use increasing dose amounts of the drug to see how safe and bearable it is. The study will also test how well PBGENE-HBV works and how it is processed by the body.
Chongqing Precision Biotech Co., Ltd
Chronic Hepatitis B
1 trial -
Anti-CD123 CAR NK cells
Chongqing Precision Biotech Co., Ltd
AML (Acute Myeloid Leukemia)
1 trial -
Anti-CD19 UCAR-T cells
Chongqing Precision Biotech Co., Ltd
Dermatomyositis, Juvenile
1 trial -
Anti-CD5 CAR NK cells
Chongqing Precision Biotech Co., Ltd
T-ALL/Lymphoma
1 trial -
BCMA/CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Systemic Lupus Erythematosus
1 trial -
BCMA/CD70-targetd CAR-T
Chongqing Precision Biotech Co., Ltd
Juvenile Dermatomyositis (JDM)
1 trial -
BGM-2121
Chongqing Precision Biotech Co., Ltd
Advanced Solid Tumors
1 trial -
C-4-29 Cells
Chongqing Precision Biotech Co., Ltd
Multiple Myeloma in Relapse
1 trial -
CAR-T cells
Chongqing Precision Biotech Co., Ltd
Relapsed Non-Hodgkin Lymphoma
1 trial -
CD19 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Systemic Lupus Erythematosus
1 trial -
CD19 targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
SLE (Systemic Lupus)
1 trial -
CD19-targetd CAR-T
Chongqing Precision Biotech Co., Ltd
Juvenile Dermatomyositis
1 trial -
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Metastatic Tumor
4 trials -
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Ovarian Cancer
1 trial -
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Renal Cell Carcinoma
1 trial -
CD70-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
Renal Cell Carcinoma (RCC)
1 trial -
CEA CAR-T cells
Chongqing Precision Biotech Co., Ltd
Gastric Cancer
1 trial -
CEA CAR-T cells
Chongqing Precision Biotech Co., Ltd
Colorectal Cancer
1 trial -
CEA-targeted CAR-T (Intravenous)
Chongqing Precision Biotech Co., Ltd
NSCLC (Advanced Non-small Cell Lung Cancer)
1 trial -
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
Peritoneal Metastases From Colorectal Cancer
1 trial -
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
Lung Cancer
1 trial -
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
Colorectal Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources